The pharmaceutical industry’s biggest lobbying group is scheduled to meet with President Donald Trump on Thursday, according ...

The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study.

Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

The best way to beat persistent inflation is to invest in businesses unaffected by rising prices, like these four high-yield ...

Pfizer (NYSE: PFE) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent ...

Secured three additional regulatory approvals for world's first chikungunya vaccine, IXCHIQ ® (Canada, Europe, UK); filed adolescent label extension submissions; awarded new $41.3 million grant from ...

For tech companies, the healthcare vertical is now the fastest growing business. The US, which spends about $5 trillion on ...

Pfizer (PFE) is a pharmaceutical and biotechnology company valued at $145 billion by market capitalization. While the company ...

The respiratory syncytial virus (RSV) vaccine triggered strong immune responses among people aged 60 years and older during ...

Buy low, sell high. That has been a good strategy for investors for a long time. However, finding great stocks to buy under ...